干旱区生态环境知识资源中心(Arid): A Review of Omadacycline for Potential Utility in the Military Health System for the Treatment of Wound Infections

Arid

DOI	10.1093/milmed/usad417
	A Review of Omadacycline for Potential Utility in the Military Health System for the Treatment of Wound Infections
	Zurawski, Daniel, V; Serio, Alisa W.; Black, Chad; Pybus, Brandon; Akers, Kevin S.; Deck, Daniel H.; Johnson, Sheila; Chattagul, Supaksorn; Noble, Schroeder M.; Raynor, Malik; Lanteri, Charlotte A.
通讯作者	Zurawski, DV
来源期刊	MILITARY MEDICINE
ISSN	0026-4075
EISSN	1930-613X
出版年	2024
卷号	189 期号:5-6 页码:e1353-e1361
英文摘要	Introduction Combat-related wound infections complicate the recovery of wounded military personnel, contributing to overall morbidity and mortality. Wound infections in combat settings present unique challenges because of the size and depth of the wounds, the need to administer emergency care in the field, and the need for subsequent treatment in military facilities. Given the increase in multidrug-resistant pathogens, a novel, broad-spectrum antibiotic is desired across this continuum of care when the standard of care fails. Omadacycline was FDA-approved in 2018 for treatment of adults with acute bacterial skin and skin structure infections (ABSSSI), as well as community-acquired bacterial pneumonia (CABP). It is a broad-spectrum antibiotic with activity against gram-positive, gram-negative, and atypical bacterial pathogens, including multidrug-resistant species. Omadacycline can overcome commonly reported tetracycline resistance mechanisms, ribosomal protection proteins, and efflux pumps, and is available in once-daily intravenous or oral formulations. In this review, we discuss the potential role of omadacycline, which is included in the Department of Defense Formulary, in the context of combat wound infections.Materials and Methods A literature review was undertaken for manuscripts published before July 21, 2023. This included a series of publications found via PubMed and a bibliography made publicly available on the Paratek Pharmaceuticals, Inc. website. Publications presenting primary data published in English on omadacycline in relation to ESKAPEE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Escherichia coli, and Enterobacter species) pathogens and Clostridioides difficile, including in vitro, in vivo, and clinical data were included.Results Of 260 identified records, 66 were included for evidence review. Omadacycline has in vitro activity against almost all the ESKAPEE pathogens, apart from P. aeruginosa. Importantly, it has activity against the four most prevalent bacterial pathogens that cause wound infections in the military healthcare system: S. aureus, including methicillin-resistant S. aureus, A. baumannii, K. pneumoniae, and E. coli. In vivo studies in rats have shown that omadacycline is rapidly distributed in most tissues, with the highest tissue-to-blood concentration ratios in bone mineral. The clinical efficacy of omadacycline has been assessed in three separate Phase 3 studies in patients with ABSSSI (OASIS-1 and OASIS-2) and with CABP (OPTIC). Overall, omadacycline has an established safety profile in the treatment of both ABSSSI and CABP.Conclusions Omadacycline has broad-spectrum activity, the option to be orally administered and an established safety profile, making it a potentially attractive replacement for moxifloxacin in the military individual first aid kit, especially when accounting for the increasing resistance to fluoroquinolones. Further studies and clinical evaluation are warranted to support broader use of omadacycline to treat combat wound infections in the military healthcare system.
类型	Review
语种	英语
开放获取类型	hybrid
收录类别	SCI-E
WOS记录号	WOS:001100821000001
WOS关键词	ACUTE BACTERIAL SKIN ; PHARMACODYNAMICS ; PHARMACOKINETICS ; COMPLICATIONS ; PREVENTION ; INJURY ; CARE
WOS类目	Medicine, General & Internal
WOS研究方向	General & Internal Medicine
资源类型	期刊论文
条目标识符	http://119.78.100.177/qdio/handle/2XILL650/404924
推荐引用方式 GB/T 7714	Zurawski, Daniel, V,Serio, Alisa W.,Black, Chad,et al. A Review of Omadacycline for Potential Utility in the Military Health System for the Treatment of Wound Infections[J],2024,189(5-6):e1353-e1361.
APA	Zurawski, Daniel, V.,Serio, Alisa W..,Black, Chad.,Pybus, Brandon.,Akers, Kevin S..,...&Lanteri, Charlotte A..(2024).A Review of Omadacycline for Potential Utility in the Military Health System for the Treatment of Wound Infections.MILITARY MEDICINE,189(5-6),e1353-e1361.
MLA	Zurawski, Daniel, V,et al."A Review of Omadacycline for Potential Utility in the Military Health System for the Treatment of Wound Infections".MILITARY MEDICINE 189.5-6(2024):e1353-e1361.